Why do some people think that Paxlovid does little or nothing for COVID?
The usual suspects…
Does Paxlovid Do Little Or Nothing for COVID?
But isn’t that a real study in the New England Journal of Medicine that they posted about?
It sure is!
And the study did find that Paxlovid wasn’t any better than placebo.
So Paxlovid really did little or nothing for these COVID patients.
“The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir–ritonavir and those who received placebo.”
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
Wait, what?
Anti-vax folks are leaving something out when they talk about the study though.
“The current phase 2–3 trial evaluated the efficacy and safety of nirmatrelvir–ritonavir in nonhospitalized adults with symptomatic Covid-19 who either were at standard risk for severe Covid-19 (i.e., without risk factors for severe Covid-19, either unvaccinated or without vaccination within the previous 12 months) or were fully vaccinated and at high risk for progression to severe Covid-19.”
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
The EPIC-SR trial refers to the Evaluation of Protease Inhibition for Covid-19 in Standard-Risk Patients.
Paxlovid Misinformation
We already know that Paxlovid works in high risk patients.
“Nirmatrelvir–ritonavir (Paxlovid [Pfizer]) is used as first-line therapy for nonhospitalized persons with Covid-19 on the basis of the results of the Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients (EPIC-HR) trial, which showed that this medication reduced the risk of hospitalization or death by 88%. The EPIC-HR trial enrolled adults who had not received a SARS-CoV-2 vaccine and who were at high risk for progression to severe Covid-19.”
Treating Acute Covid-19 — Final Chapters Still Unwritten
So they did a study to see if Paxlovid worked as well in those who were either vaccinated or did not have risk factors for severe disease.
“The trial was notable for including younger participants: The median age was 42 years, and only 5% were 65 years of age or older. Michael Osterholm, PhD, MPH, director of the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP), publisher of CIDRAP News, cautioned that the study’s young participant population changed how risk was defined in the study.”
Among fully vaccinated, study shows Paxlovid does not shorten symptoms
Unfortunately, it didn’t.
“This result supports guidelines that recommend nirmatrelvir–ritonavir only for persons who are at high risk for disease progression.”
Treating Acute Covid-19 — Final Chapters Still Unwritten
So yes, Esai Morales should have tried to learn a little more before posting, unless of course he is simply one of the misinformed misinformers gaslighting people with Paxlovid misinformation…
More on COVID Misinformation
- More Questions to Help You Become a Vaccine Skeptic
- Treating Acute Covid-19 — Final Chapters Still Unwritten
- Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
- Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications
- Among fully vaccinated, study shows Paxlovid does not shorten symptoms
- Paxlovid for COVID-19
- Why COVID-19 patients who could most benefit from Paxlovid still aren’t getting it
- Post Omits Paxlovid’s Ability to Protect Against Severe COVID-19, Death
- Everything you need to know about Paxlovid — especially, should you take it?
- Q&A On Paxlovid, Pfizer’s COVID-19 Oral Antiviral
- COVID-19 Misconceptions
Last Updated on April 8, 2024